source
- Massachusetts biotech sees record-first-half VC funding and IPO surge despite modest NIH funding dipThe latest MassBio Industry Snapshot reports a strong start to 2026 for the state’s biotech sector, with venture capital inflows rising 25% year over year to $3.45 billion in the first half of the…
- FDA grants three-month extension for Capricor’s Duchenne therapy deramiocel, sets new action date Nov 22The U.S. Food and Drug Administration has given Capricor Therapeutics a three‑month extension to review additional data for its Duchenne muscular dystrophy cell therapy, deramiocel. The agency has…